Scientific American2d
Artificial Intelligence is Reshaping Healthcare
Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...
Medscape2d
3D Total Body Photography Shown to Decrease Biopsies, Improve Dx of Nonmelanoma Skin Cancers
Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces ...
Novartis scraps use of diverse panels for hires in US
Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told ...
Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...
Medscape3d
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'
TOKYO (Reuters) -Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy ...
BioSpace2d
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...
Fierce Pharma2d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
BioPharma Dive3d
Novartis builds case for new SMA gene therapy
To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...
Fierce Pharma2d
Novartis links music and science in corporate campaign tied to Eurovision sponsorship
Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...